IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Safety of Recombinant Human Thrombopoietin in Adults after Related Donor Haploidentical Haematopoietic Stem Cell Transplantation A Pilot Study
Liu, Dai-Hong; Huang, Xiao-Jun; Liu, Kai-Yan; Xu, Lan-Ping; Chen, Yu-Hong; Wang, Yu; Han, Wei; Chen, Huan
刊名CLINICAL DRUG INVESTIGATION
2011
31期:2页:135-141
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]BONE-MARROW-TRANSPLANTATION ; HUMAN MEGAKARYOCYTE GROWTH ; PHASE-I TRIAL ; HEMATOLOGIC MALIGNANCIES ; ADVANCED CANCER ; VITRO ; THROMBOCYTOPENIA ; CHEMOTHERAPY ; DEPLETION ; DISEASE
英文摘要

Background and Objective: Delayed recovery of platelets can be found in recipients of related donor haploidentical haematopoietic stem cell transplantation (HSCT). The objective of this study was to evaluate the safety of recombinant human thrombopoietin (rhTPO) administration prior to engraftment in patients who received related donor haploidentical HSCT.

Methods: Nineteen patients with haematological malignancies received rhTPO prior to platelet engraftment after related donor haploidentical HSCT. Safety and tolerability levels together with the influence of rhTPO on the outcome of transplantation were evaluated.

Results: Slight elevations in ALT and/or AST were observed in five patients; in two other patients, bilirubin levels increased slightly. No significant changes in routine examination findings and no allergic reactions were observed during the study period. Eighteen patients achieved platelet engraftment at a median of 16 (range 11-34) days. The cumulative +/- SD incidence of acute graft-versus-host disease (GVHD) grade 1-4 at +100 days was 68.4 +/- 10.7%, and that of chronic GVHD at 3 years was 24.7 +/- 10.7%. Nine (47.4%) patients survived free of relapse, with a median follow-up of 1631 (1550-1734) days after transplantation.

Conclusion: Early administration of rhTPO prior to engraftment was safe and well tolerated in patients receiving related donor haploidentical HSCT.

语种英语
WOS记录号WOS:000286027500006
引用统计
被引频次:5[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64116
专题北京大学第二临床医学院_血液科
医学人文研究院/公共教学部_哲学与社会科学系
作者单位Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Liu, Dai-Hong,Huang, Xiao-Jun,Liu, Kai-Yan,et al. Safety of Recombinant Human Thrombopoietin in Adults after Related Donor Haploidentical Haematopoietic Stem Cell Transplantation A Pilot Study[J]. CLINICAL DRUG INVESTIGATION,2011,31(2):135-141.
APA Liu, Dai-Hong.,Huang, Xiao-Jun.,Liu, Kai-Yan.,Xu, Lan-Ping.,Chen, Yu-Hong.,...&Chen, Huan.(2011).Safety of Recombinant Human Thrombopoietin in Adults after Related Donor Haploidentical Haematopoietic Stem Cell Transplantation A Pilot Study.CLINICAL DRUG INVESTIGATION,31(2),135-141.
MLA Liu, Dai-Hong,et al."Safety of Recombinant Human Thrombopoietin in Adults after Related Donor Haploidentical Haematopoietic Stem Cell Transplantation A Pilot Study".CLINICAL DRUG INVESTIGATION 31.2(2011):135-141.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liu, Dai-Hong]的文章
[Huang, Xiao-Jun]的文章
[Liu, Kai-Yan]的文章
百度学术
百度学术中相似的文章
[Liu, Dai-Hong]的文章
[Huang, Xiao-Jun]的文章
[Liu, Kai-Yan]的文章
必应学术
必应学术中相似的文章
[Liu, Dai-Hong]的文章
[Huang, Xiao-Jun]的文章
[Liu, Kai-Yan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。